
Measuring the invisible
to personalise care
Our approach enables more personalised patient monitoring by transforming everyday data into drivers of progress for medical practice and research.
Connecting key healthcare stakeholders
to address their real needs

For the Pharmaceutical industry:
Maximise therapeutic impact.
We accelerate the understanding of pathologies and the validation of treatment efficacy through high-quality real-world clinical evidence (RWE).

For Physicians:
Towards personalised medicine
Reliable, continuous data to reduce uncertainty between consultations.

For Patients:
Take control of your health.
The patient becomes an engaged and active participant in their own medical monitoring.
The Science of Biomarkers:
Transforming raw data into clinical value
A digital biomarker is the result of transforming raw data, collected actively or passively via the embedded sensors of a smartphone.
The Ptosis example
Myasthenia Gravis is an autoimmune disease characterised by symptoms that fluctuate from hour to hour and day to day. The gap between physical consultations makes it complex for healthcare professionals to monitor these daily variations.
The challenge: The absence of reliable, closely-spaced data between appointments limits a fine understanding of how the pathology evolves.
Raw data collection
Use of motion sensors
(accelerometer,
gyroscope), location (GPS),
interaction (screen)
or sound (microphone).

Raw data collection
Use of motion sensors (accelerometer, gyroscope), location (GPS), interaction (screen) or sound (microphone).

The Ptosis example
Myasthenia Gravis is an autoimmune disease characterised by symptoms that fluctuate from hour to hour and day to day. The gap between physical consultations makes it complex for healthcare professionals to monitor these daily variations.
The challenge: The absence of reliable, closely-spaced data between appointments limits a fine understanding of how the pathology evolves.
An engine for pharma:
Accelerating the drug lifecycle
We intervene across the entire product lifecycle, from Phase I to real-world evidence (RWE), to generate high-precision clinical evidence. As a strategic partner, we help healthcare stakeholders transform data into a lever for growth and differentiation.

Clinical Trials (Phase I – Phase IV)
Generation of new indicators on treatment efficacy.
Post-Market & Real-World Evidence
Continuous monitoring in routine clinical practice to facilitate market access and generate real-world impact evidence (RWE).

